ストックスクリーナーアプリを入手
4.02
0.00%
0.00
アフターアワーズ：
4.03
0.01
+0.25%
Tvardi Therapeutics Inc (TVRD) 最新ニュース
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Average Price Target from Brokerages - Defense World
Growth Report: Is Tvardi Therapeutics Inc attractive for institutional investorsInsider Selling & Entry Point Confirmation Alerts - baoquankhu1.vn
Tvardi Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | 0HTC | US1407553072 - marketscreener.com
CARA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Free cash flow per share of Tvardi Therapeutics Inc. – FWB:69C - TradingView
Tvardi Therapeutics, Inc. (TVRD): Investor Outlook on the Biotech Company’s 125% Potential Upside - DirectorsTalk Interviews
MSN Money - MSN
Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: Exploring a Potential 140% Upside in Biotechnology - DirectorsTalk Interviews
Will Tvardi Therapeutics Inc. (69C) stock sustain uptrend momentumTrade Performance Summary & Risk Managed Investment Entry Signals - mfd.ru
Will Tvardi Therapeutics Inc. outperform during market ralliesJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - mfd.ru
What is Tvardi Therapeutics Inc.’s book value per shareJuly 2025 Macro Moves & Long-Term Growth Plans - mfd.ru
Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: A Look at the 129% Potential Upside in Biotech - DirectorsTalk Interviews
Published on: 2026-02-12 23:10:23 - mfd.ru
Will Tvardi Therapeutics Inc. stock maintain dividend yield2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
Tvardi Therapeutics to Participate in Upcoming Investor Conferences - marketscreener.com
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - GlobeNewswire Inc.
We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate - Yahoo Finance
Tvardi Therapeutics (NASDAQ:TVRD) Rating Increased to Hold at Wall Street Zen - Defense World
Risk Report: Is BRLSW affected by consumer sentimentWeekly Gains Summary & Verified Entry Point Detection - baoquankhu1.vn
Tvardi Therapeutics (NASDAQ:TVRD) Raised to Strong-Buy at Lucid Cap Mkts - Defense World
Lucid Capital Markets upgrades Tvardi Therapeutics stock to Buy on valuation - Investing.com Nigeria
Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital - TipRanks
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials - MSN
Growth Report: Can Tvardi Therapeutics Inc sustain its profitabilityJuly 2025 Final Week & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
What is the long term forecast for Tvardi Therapeutics Inc. stockWeekly Stock Analysis & Capital Efficient Trade Techniques - mfd.ru
MACD Signal: What is the cash position of BEEPJuly 2025 Drop Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Is Tvardi Therapeutics (NASDAQ:TVRD) In A Good Position To Deliver On Growth Plans? - simplywall.st
Tvardi Therapeutics (NASDAQ:TVRD) Lowered to Sell Rating by Wall Street Zen - Defense World
Tvardi Therapeutics, Inc. (TVRD) Investor Outlook: Exploring an 84% Potential Upside in Innovative Biotech - DirectorsTalk Interviews
Quarterly Earnings: What hedge funds are buying Tvardi Therapeutics Inc2025 Support & Resistance & Verified Short-Term Plans - baoquankhu1.vn
New Highs: How correlated is Tvardi Therapeutics Inc to the S P500July 2025 Short Interest & Trade Opportunity Analysis Reports - baoquankhu1.vn
Tvardi Therapeutics, Inc. Updates on Clinical Trials and Pipeline Progress - TradingView
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Average Recommendation of “Hold” by Brokerages - Defense World
Why retail investors favor Tvardi Therapeutics Inc. stockQuarterly Growth Report & Low Volatility Stock Suggestions - Улправда
Will Tvardi Therapeutics Inc. (69C) stock gain from green policies2025 Technical Patterns & Expert Approved Trade Ideas - ulpravda.ru
Tvardi reports improved fibrosis scores with TTI-101 in IPF trial - Investing.com Nigeria
Will Tvardi Therapeutics Inc. stock split attract more investorsWeekly Gains Summary & Technical Buy Zone Confirmation - Улправда
Can Tvardi Therapeutics Inc. stock outperform in 2025 bull market2025 Support & Resistance & Low Volatility Stock Suggestions - Улправда
Will Tvardi Therapeutics Inc. stock recover faster than peersPortfolio Performance Report & Free Technical Confirmation Trade Alerts - Улправда
Can Tvardi Therapeutics Inc. (69C) stock stage a strong rebound this quarterWeekly Investment Report & Weekly High Return Forecasts - Улправда
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Risk Analysis: Will Tvardi Therapeutics Inc. stock split attract more investorsInflation Watch & Real-Time Stock Movement Alerts - Улправда
Why Tvardi Therapeutics Inc stock is seen as undervaluedWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - moha.gov.vn
Tvardi Therapeutics TTI-101 shows 9.4% fibrosis score decrease versus 2.4% placebo - marketscreener.com
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights - The Manila Times
Street Watch: Can Tvardi Therapeutics Inc stock outperform in 2025 bull marketWeekly Risk Report & Safe Capital Investment Plans - Bộ Nội Vụ
Tvardi Therapeutics (NASDAQ:TVRD) Upgraded at Wall Street Zen - Defense World
Will Q4 Earnings Be a Catalyst for Cubex Tubings LimitedEconomic Data Impact & Free Hedging Tactics for Volatile Markets - earlytimes.in
Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today? - MSN
Tvardi Therapeutics, Inc. (TVRD) Total Expenses (TTM) - Zacks Investment Research
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):